Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations.

Voss MH, Hierro C, Heist RS, Cleary JM, Meric-Bernstam F, Tabernero J, Janku F, Gandhi L, Iafrate AJ, Borger DR, Ishii N, Hu Y, Kirpicheva Y, Nicolas-Metral V, Pokorska-Bocci A, Vaslin Chessex A, Zanna C, Flaherty KT, Baselga J.

Clin Cancer Res. 2019 May 1;25(9):2699-2707. doi: 10.1158/1078-0432.CCR-18-1959. Epub 2019 Feb 11.

PMID:
30745300
2.

Bone and Joint Tissue Penetration of the Staphylococcus-Selective Antibiotic Afabicin in Patients Undergoing Elective Hip Replacement Surgery.

Menetrey A, Janin A, Pullman J, Overcash JS, Haouala A, Leylavergne F, Turbe L, Wittke F, Nicolas-Métral V.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e01669-18. doi: 10.1128/AAC.01669-18. Print 2019 Mar.

3.

The effects of CYP3A4 induction and inhibition on the pharmacokinetics of alisporivir in humans.

Barve A, Kovacs SJ, Ke J, Crabbe R, Grosgurin P, Menetrey A, Nicolas-Métral V, Dabovic K, Dole K, Zhang J, Praestgaard J, Sunkara G, Stein D.

Clin Pharmacol Drug Dev. 2015 Jan;4(1):25-32. doi: 10.1002/cpdd.114. Epub 2014 May 26.

PMID:
27128001
4.

The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients.

Flisiak R, Feinman SV, Jablkowski M, Horban A, Kryczka W, Pawlowska M, Heathcote JE, Mazzella G, Vandelli C, Nicolas-Métral V, Grosgurin P, Liz JS, Scalfaro P, Porchet H, Crabbé R.

Hepatology. 2009 May;49(5):1460-8. doi: 10.1002/hep.22835.

PMID:
19353740
5.

An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C.

Crabbé R, Vuagniaux G, Dumont JM, Nicolas-Métral V, Marfurt J, Novaroli L.

Expert Opin Investig Drugs. 2009 Feb;18(2):211-20. doi: 10.1517/13543780802651583 . Review.

PMID:
19236267
6.

The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.

Flisiak R, Horban A, Gallay P, Bobardt M, Selvarajah S, Wiercinska-Drapalo A, Siwak E, Cielniak I, Higersberger J, Kierkus J, Aeschlimann C, Grosgurin P, Nicolas-Métral V, Dumont JM, Porchet H, Crabbé R, Scalfaro P.

Hepatology. 2008 Mar;47(3):817-26. doi: 10.1002/hep.22131.

PMID:
18302285
7.

Pharmacological control of cellular calcium handling in dystrophic skeletal muscle.

Ruegg UT, Nicolas-Métral V, Challet C, Bernard-Hélary K, Dorchies OM, Wagner S, Buetler TM.

Neuromuscul Disord. 2002 Oct;12 Suppl 1:S155-61. Review.

PMID:
12206810
8.

A human cellular model for studying the regulation of glucagon-like peptide-1 secretion.

Reimer RA, Darimont C, Gremlich S, Nicolas-Métral V, Rüegg UT, Macé K.

Endocrinology. 2001 Oct;142(10):4522-8.

PMID:
11564718
9.

Mdx myotubes have normal excitability but show reduced contraction-relaxation dynamics.

Nicolas-Metral V, Raddatz E, Kucera P, Ruegg UT.

J Muscle Res Cell Motil. 2001;22(1):69-75.

PMID:
11563551
10.

Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts.

Ogilvie M, Yu X, Nicolas-Metral V, Pulido SM, Liu C, Ruegg UT, Noguchi CT.

J Biol Chem. 2000 Dec 15;275(50):39754-61.

Supplemental Content

Loading ...
Support Center